This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Wednesday, May 4, 2016
Hepatitis C Deaths in U.S. Rose in 2014, but New Drugs Hold Promise
Hepatitis C Deaths in U.S. Rose in 2014, but New Drugs Hold Promise
By ABBY GOODNOUGH
MAY 4, 2016
WASHINGTON — Deaths from hepatitis C in the United States continued climbing in 2014, the Centers for Disease Control and Prevention reported on Wednesday, but experts hope the trend will reverse over the next few years as more people with the virus receive highly effective new treatments.
Dr. Ward said the agency’s goal was a decline of at least 15 percent in deaths associated with hepatitis C over the next five years. But public health officials face another huge challenge in slowing the rapid rise of hepatitis C infection among young people swallowed by the opioid epidemic. Acute cases of hepatitis C have more than doubled since 2010, according to the agency, with the new cases mostly among young, white drug injectors in rural and suburban areas. Dr. Ward said the agency believed as many as 30,000 people were acquiring hepatitis C each year.
No comments:
Post a Comment